GlaxoSmithKline (GSK) Will Stop Paying Doctors to Promote Drugs

Kermit Cole
1
73

In a first for a major drug company, GlaxoSmithKline, the British pharma that was fined $3 billion for illegal marketing of Paxil and Wellbutrin, has said that by 2016 it will no longer pay doctors to promote its drugs and will stop tying sales representatives’ compensation to the number of prescriptions doctors write.  GSK will also stop providing doctors with financial support to attend conferences.

Article →

Previous article“I Overmedicated My Kid: Big Pharma’s Attention Obsession Puts Children at Risk”
Next articlePower to Communities,
Healing Through Social Justice:
INTAR 2014 in Liverpool, England
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]

1 COMMENT

  1. That…is….wonderful. I’m sure its to protect their legal back, and to appear less tainted, but the end result is a good one and should be followed by all pharmaceutical manufacturers.

    No more doctors getting paid to promote pharmaceuticals.

    And now for the next big lion step. No more advertising pharmaceuticals. And then next, only neutral party double blind longitudinal studies of drugs. “Evidence” of drug efficacy by the company itself should be ignored. These neutral party studies can then be written up in medical journals without ties to big Pharma.

    Good first step though.

LEAVE A REPLY